The quinolone class of antimicrobial agents has generated considerable interest since its discovery 140 years ago. Substantial progress has been made in our understanding of the molecular mechanisms of the action of quinolones against pathogenic bacteria, the induction of resistance to quinolones in these organisms, and the potential of each quinolone compound to induce toxicity in treated patients. Here, these key discoveries are reviewed; the present indications approved by regulatory agencies are described in detail, with comments on adverse events caused by quinolones in treated patients; and speculation about the future of the quinolones is proffered, even though their future is difficult to predict, because many factors may affect their clinical usefulness. However, the emergence of bacterial resistance to the quinolones is a major factor that will determine the future clinical effectiveness of these agents, so that intense investigation of mechanisms to either prevent or curtail resistance to quinolones is of prime importance to their future.
(SARs) of the quinolones, with respect to their relative susceptibilities to the development of bacterial resistance and their potential for causing adverse events in treated patients [3, 4] .
Molecular mechanisms of action. Bacteria face a major topological problem, because each bacterium contains a chromosome that is composed of doublestranded DNA, which is 1300 mm long, but the average bacterium is only 2 mm long and 1 mm wide. In 1974, a study by Worcel [5] helped to explain how the chromosome was packed in Escherichia coli. Worcel observed that the chromosome is subdivided into ∼65 regions, which he called "domains," each of which is ∼20 mm long and is attached to an RNA core. The size of each domain is reduced by "negative supertwisting"-that is, supertwisting that occurs against the normal direction of the helical state of DNA in its linear form [6, 7] . In 1976, Crumplin and Smith [8] discovered that the quinolone nalidixic acid caused abnormal accumulation of single-stranded DNA precursors and that, when each chromosomal domain was supercoiled, it was also transiently nicked. Furthermore, when supercoiling was completed, the single-stranded DNA state was abolished by the sealing action of an enzyme that was specifically inhibited by the quinolone. These observations helped to explain the mechanism of action of the quinolones against bacteria [7] [8] [9] . Subsequently, Gellert et al. [10] identified this enzyme that nicks double-stranded chromosomal DNA, introduces negative supercoils, and then seals the nicked DNA, and they called it "DNA gyrase" (or "topoisomerase II") [11, 12] . These observations provided a molecular basis for the potent antibacterial effects of the newer quinolones. Subsequently, 4 DNA topoisomerases were identified in bacteria [4, 13] . Topoisomerases I and III are not very susceptible to inhibition by the quinolones, whereas topoisomerases II and IV are the 2 major targets of quinolones. Both topoisomerases II and IV are tetrameric structures and are composed of 2 subunit pairs. There are 4 subunits in topoisomerase II: 2 A monomers and 2 B monomers, which are known as "Gyr A" and "Gyr B," to denote DNA gyrase [14, 15] . Topoisomerase IV also has A and B subunits that are encoded by the parC and parE genes. Topoisomerase IV is involved with decatenation of the linked DNA molecules in the bacterial cell [13] . Thus, topoisomerases II and IV are the lethal targets of the quinolones. Their identification has led to the development of new quinolones that have increased activity against topoisomerases II and IV [4, 13, 16] .
Modifications to the quinolone nucleus.
A new key finding in the evolution of quinolones was modification of the quinolone nucleus through the addition of different substituents at the N-1, C-6, C-7, and C-8 positions [4, 13] (see also figure 1 in Owens and Ambrose [17] ). These modifications altered the antimicrobial activity, pharmacokinetics, and metabolic properties of the quinolones and provided a better understanding of the SARs in quinolone compounds. The addition of specifically selected substituents at these key positions on the quinolone nucleus made it possible to target specific groups of bacteria and to improve the pharmacokinetics of the earlier quinolone compounds [18] [19] [20] . Some of the key changes included the addition of a fluorine atom at position C-6, which increased DNA gyrase inhibitory activity, facilitated penetration into the bacterial cell, and provided activity against staphylococci. The addition of a second fluorine group at position C-8 resulted in increased absorption and a longer elimination half-life but also increased phototoxicity. The addition of a piperazine group at position C-7 provided the greatest activity against aerobic gram-negative bacteria and increased the activity against both staphylococci and Pseudomonas species. Alkylation of the C-7 ring improved the activity against aerobic gram-positive bacteria and increased the elimination half-life of quinolone compounds. The addition of a methyl group to the distal nitrogen of the C-7 piperazine ring also increased the elimination half-life and improved bioavailability. Finally, the addition of a cyclopropyl group at position N-1 yielded ciprofloxacin, which has increased antibacterial activity against aerobic gram-positive and gram-negative pathogens. In addition, increased activity against Mycoplasma and Chlamydia species was achieved by adding an amino group at C-5 and a fluorine group at C-8 to quinolone compounds that possessed a cyclopropyl group at N-1 [3] . Similarly, overall antibacterial activity could be enhanced by simply adding a fluorine or a chlorine at C-8 to compounds with a cyclopropyl group at N-1 [19] . The most recent key modification was the observation that the addition of a methoxy group, instead of a halide, at the C-8 position specifically targets both topoisomerase II and IV, which also may decrease the possibility of the development of resistance to quinolones [18, 20] . Of the currently available agents, only gatifloxacin and moxifloxacin have a C-8 methoxy group in their chemical structure.
Effect on antimicrobial activity. Differences in the in vitro activity of the fluoroquinolones primarily form the basis of their classification, as shown in table 1. The antimicrobial activity of the early, first-generation quinolones (i.e., nalidixic acid, oxolinic acid, cinoxacin, piromidic acid, pipemidic acid, and flumequine) was excellent against aerobic, gram-negative bacteria. However, first-generation quinolones were not very active against aerobic, gram-positive bacteria or anaerobic bacteria. In 1980, the second-generation quinolones were introduced when norfloxacin was synthesized by adding a fluorine at C-6 and a cyclic diamine piperazine at C-7 [13] . These changes added antimicrobial activity against aerobic gram-positive bacteria and improved activity against gram-negative bacteria, compared with the first-generation compounds, but the second-generation quinolones still lacked activity against anaerobic bacteria. Norfloxacin was the first of the "fluoroquinolones," a name resulting from the addition of a fluorine at the C-6 position. Other second-generation quinolones include ciprofloxacin, ofloxacin, levofloxacin, enoxacin, fleroxacin, lomefloxacin, pefloxacin, and rufloxacin [4] . Newer fluoroquinolones (i.e., third-generation fluoroquinolones, including grepafloxacin, gatifloxacin, sparfloxacin, temafloxacin, tosufloxacin, and pazufloxacin) were subsequently developed and had greater potency against gram-positive bacteria, particularly pneumococci; they also had good activity against anaerobic bacteria. The final group of compounds (i.e., trovafloxacin, clinafloxacin, sitafloxacin, moxifloxacin, and gemifloxacin) was termed "fourth-generation fluoroquinolones," because they had potent activity against anaerobes and increased activity against pneumococci [4, 13] . Although there are a number of ways to categorize quinolones (i.e., by chemical structure, by SARs, by in vitro spectrum of antimicrobial activity, or by clinical efficacy), these classifications clearly are arbitrary. The aforementioned classification system-first to fourth generation-is based on the newest spectrum of antibacterial activity and potency against pneumococci and anaerobic organisms and provides a practical classification system for clinical use [4] .
Effect on pharmacokinetics. In early studies, the quinolones were observed to have excellent oral absorption, good distribution in tissue, with excellent interstitial fluid levels, entry into phagocytic cells, and urinary concentrations that exceeded the MICs for many common pathogens [21] . Key structural modifications resulted in improved pharmacokinetics (e.g., a longer elimination half-life, which permitted once-daily dosing and better tissue penetration) of some of the newest quinolones, including gatifloxacin, gemifloxacin, grepafloxacin, moxifloxacin, sitafloxacin, sparfloxacin, and trovafloxacin [18, 19, [21] [22] [23] . Specific modifications included alkylation of the quinolones, which improved elimination half-life and penetration into tissue; the addition of 2 methyl groups to the C-7 piperazine ring, which increased oral efficacy; the addition of an amino group at C-5, which increased lipophilicity; and the addition of a halogen at position C-8, which improved in vivo activity [4, 13, 19] .
Effect on resistance and adverse events. Progress in our understanding of the role of SARs, along with the application of current research techniques, has indicated that bacterial resistance to quinolones occurs either with the induction of amino acid changes in specific areas of the parC and parE genes of topoisomerase IV, particularly in pneumococci, and in the gyrA gene of topoisomerase II, in staphylococci, or with amino acid changes in both topoisomerases II and IV in many bacterial species [24] [25] [26] [27] [28] . The specific areas of these genes are known as "quinolone resistance-determining regions" (QRDRs). Moderate resistance can also occur because of increased efflux of the quinolone out of the bacterial cell, which reduces intracellular concentrations of the drug. Key observations have demonstrated that, not only is the level of resistance different among various quinolones, but it also is different among the various species of bacteria [13, 19, [28] [29] [30] [31] .
The incidence of adverse events observed in association with the early-generation quinolones was low; adverse events frequently appeared within the first several days of treatment and occurred with similar frequencies in both young and elderly patients, except that CNS adverse events occurred more frequently in elderly patients [32, 33] . The rate of adverse events associated with both oral and intravenous fluoroquinolones appears to be dose related, with an increasing incidence of adverse events associated with increasing doses and duration of therapy [32, 33] . In any event, fluoroquinolones are considered to be relatively safe, compared with other classes of commonly used antimicrobial agents [4, 18, 32, 33] . Gastrointestinal disturbances have been reported most frequently, followed by CNS adverse effects, hypersensitivity reactions, and, quite rarely, hypotension, tachycardia, crystalluria, thrombocytopenia, leukopenia, and anemia. Some of the early quinolones interacted with theophylline and caffeine and other quinolone compounds (i.e., those that have a fluorine in the C-8 position) and produced moderate-to-severe phototoxicity, because they accumulated in high concentrations in skin. Phototoxicity is more common and more severe in association with the use of lomefloxacin, fleroxacin, and sparfloxacin and is much rarer in association with the use of (in descending order) grepafloxacin, ofloxacin, ciprofloxacin, levofloxacin, and trovafloxacin. Phototoxicity reactions have not been reported in association with moxifloxacin and gatifloxacin [4, 32, 33] . Fortunately, phototoxicity is not a problem associated with the fluoroquinolones currently in common use. Three adverse events associated with quinolones-cardiotoxicity (e.g., prolongation of the corrected QT interval), hepatotoxicity, and hypoglycemia-currently command the most attention [4, 32, 33] . The naphthyridone quinolones (i.e., nalidixic acid, piromidic and pipemidic acid, enoxacin, tosufloxacin, trovafloxacin, and gemifloxacin) have 2 nitrogens in their basic nuclei-a traditional nitrogen in the 1 position and a second nitrogen in the 8 position. Some of the naphthyridone quinolones are associated with higher incidences of and a greater number of serious adverse events, compared with quinolones without a nitrogen in the 8 position.
PRESENT
A number of infectious diseases are successfully treated with quinolones administered orally or intravenously. Clinical efficacy has been demonstrated for respiratory tract infections, including acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, nosocomial pneumonia, and bacterial sinusitis. Quinolones also have documented effectiveness for treating uncomplicated (and some complicated) urinary tract infections, bacterial prostatitis, skin and other soft-tissue infections, bone and joint infections, gastrointestinal infections caused by toxigenic E. coli or Salmonella species (including typhoid and paratyphoid fevers and the chronic Salmonella carrier state), and infection with Shigella, Campylobacter, Aeromonas, and Vibrio species and Plesiomonas shigelloides. The quinolones have also been effective in treating sexually transmitted diseases, such as gonococcal and chlamydial infections, chancroid, and pelvic infections. Some quinolones have also been very useful in treating immunocompromised patients with febrile neutropenia [34] [35] [36] [37] [38] [39] [40] [41] . It should be noted that not all fluoroquinolones have been approved for use in the treatment of all of the aforementioned infections. The use of all fluoroquinolones interchangeably, especially for unapproved indications, is discouraged.
At present in the United States, the most frequently prescribed fluoroquinolones are ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin [34] . Gemifloxacin became available for general use in 2004. Ciprofloxacin is approved for use for both uncomplicated and complicated urinary tract infections, including cystitis, pyelonephritis, and chronic bacterial prostatitis; uncomplicated urogenital and rectal gonorrhea; skin and other softtissue infections; bone and joint infections; infectious diarrhea and typhoid fever; intra-abdominal infections (when used with metronidazole); sinusitis; nosocomial pneumonia. Cirpofloxacin is also approved for use as empirical therapy for patients with febrile neutropenia, as prophylaxis and treatment for anthrax, and for lower respiratory tract infections, including acute bacterial exacerbations of chronic bronchitis, pneumonia (other than pneumococcal pneumonia), hospital-acquired pneumonia, and infection with Legionella species (table 2) [34] . Levofloxacin is approved for use in treating both uncomplicated and complicated urinary tract infections (including pyelonephritis and chronic bacterial prostatitis), skin and skin structure infections, acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia (including that due to penicillin-resistant Streptococcus pneumoniae [PRSP] and multidrug-resistant S. pneumoniae [MDRSP]), and nosocomial pneumonia (table 2) [34] . Gatifloxacin is approved for use in treating both uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated urogenital gonorrhea, uncomplicated skin and skin-structure infections, acute sinusitis, and acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia (including that due to PRSP and MDRSP) (table 2) [34] . Moxifloxacin is approved for use in treating acute bacterial sinusitis, uncomplicated skin and skin-structure infections, and acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia (including that due to PRSP and MDRSP) (table 2) [34] . Gemifloxacin is approved for use in treating acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild-to-moderate severity (table 2) .
It is also worth noting that, although a quinolone may be approved to treat a specific infection, consideration must be given to the susceptibility of the infecting organism. In this context, all quinolones are not equal and should not be used interchangeably [34] . To use them most effectively, clinicians should be familiar with the specific properties and clinical indications of each quinolone. For example, ciprofloxacin continues to be an excellent choice for treating infections caused by aerobic gram-negative bacilli, including those caused by drug-susceptible P. aeruginosa.
In contrast to other classes of antimicrobial agents, the appropriate use of the quinolones-in particular for the treatment of respiratory tract infections-continues to generate much discussion among clinical investigators [42] [43] [44] [45] . One issue is the emergence of resistance to quinolones, particularly among S. pneumoniae [44, 45] and, more recently, among Haemophilus influenzae [46] . Although the overall incidence of resistance to quinolones among pneumococci is currently relatively low (!5%), the incidence is increasing, and the justifiable concern is that it will continue to increase [45] . Importantly, resistance to quinolones among pneumococci has been observed to occur in association with those quinolones that have modest in vitro activity against pneumococci [47] [48] [49] [50] [51] [52] . Therefore, the possibility exists that the use of those quinolones with the most potent in vitro activity against pneumococci may delay the emergence of resistance in these pathogens. However, future studies are required to answer this question.
Another issue of concern is whether in vitro resistance to antimicrobial agents affects clinical outcomes, particularly in pathogens responsible for serious respiratory tract infections. Recent reports suggest that in vitro resistance to b-lactams and macrolides does not correlate with either therapeutic failure or increased mortality among patients with pneumococcal pneumonia [53, 54] . If these observations are correct, then they are unique, compared with our earlier experiences with the resistance and clinical outcomes associated with infections caused by other pathogens. For instance, clinical failure was observed after the appearance of resistance to b-lactams among staphylococci, resistance to vancomycin and aminoglycoside among enterococci, multidrug resistance among Mycobacterium tuberculosis, and antiretroviral resistance among HIV. Recently, an alternative concept has been proffered that may help to explain the lack of correlation between therapeutic failure and resistance to b-lactams and macrolides among pneumococci [55] . Specifically, the problem may involve the methods used to identify pneumococci, so that misidentification results in a falsely elevated prevalence of resistance [55] . Misidentification obviously would also affect clinical evaluations. Clearly, correct identification of pneumococci in additional surveillance studies, as well as proper clinical investigation of outcomes, is needed to resolve the perplexing issue of the in vitro resistance to and clinical efficacy of quinolones used to treat respiratory tract infections.
FUTURE
The future of the quinolones is difficult to predict. Nevertheless, the quinolone nucleus continues to provide opportunities for future modifications that may produce more valuable compounds. As mentioned in earlier reviews [2] [3] [4] , future prospects of newer compounds may have (1) greater potency, particularly against staphylococci and enterococci; (2) better penetration into the CNS and cerebrospinal fluid; (3) broader and more potent activity against anaerobic bacteria; (4) greater activity against infections caused by mycobacteria and Stenotrophomonas, Pseudomonas, and Alcaligenes species, which currently are difficult to treat; (5) decreased drug-drug interactions; and (6) better patient tolerability, with lower incidences of adverse reactions and serious toxicity [2] [3] [4] . In addition, newer quinolones may be developed with greater activity against targets in infectious agents responsible for Lyme disease, malaria, nocardiosis, toxoplasmosis, pneumocystosis, leishmaniasis, fungi, and DNA viruses. However, research efforts are more likely to focus on more-common infections, rather than rare diseases or diseases for which effective therapy already exists. Another, albeit poorly explored, area is the development of new compounds with a high and specific affinity for the DNA (eukaryotic topoisomerases) in human malignant cells, which could be used alone or in combination with other chemotherapeutic agents. This potential would provide sufficient economic and humane rewards to justify the investment in such an effort [2, 4] . If the use of quinolones in clinical medicine is to continue, the emergence of bacterial resistance to the quinolones should remain of primary importance as an area of current and future research. Although much progress has been made in our understanding of the important effect of amino acid changes in the QRDR of topoisomerases and their effect on bacterial resistance, the magnitude of the importance of efflux pumps in bacterial cells provides a different and potentially productive avenue for continued investigation [56] [57] [58] [59] [60] [61] [62] [63] . The development of highly effective quinolone pump inhibitors that are safe for use in treating patients may provide a key advantage for patients receiving therapy with quinolones or other antimicrobial agents in the future.
CONCLUSIONS
This review has attempted to highlight the key discoveries made during the evolution of the quinolone class of antimicrobial agents, as well as the effect of these discoveries on the development of newer and truly innovative compounds that have clearly been effective in clinical medicine. The currently approved indications for the most commonly used quinolones have also been reviewed, along with the concern of emerging bacterial resistance to these agents. In addition, a discussion of future potential uses for newer quinolone compounds, aside from their proven efficacy as antibacterial agents, has been included. Clearly, the quinolones have captured the interest of investigators and clinicians during the past 2 decades.
